ABSTRACT To compare tissue-based pharmacokinetics and efficacy of oral tenofovir disoproxyl fumarate (TDF) versus subcutaneous tenofovir (TFV), macaques were treated for 2 weeks starting 1 week after simian immunodeficiency virus inoculation. Despite lower plasma TFV levels in the oral TDF arm, similar TFV diphosphate levels and antiviral activities were measured in lymphoid cells of most tissues. In intestinal tissues, however, oral TDF resulted in higher active drug levels, associated with lower virus levels and better immune preservation
Background: The goal of antiretroviral therapy (ART) is to suppress virus replication to limit immun...
Simple affordable interventions are needed to reduce vertical human immunodeficiency virus (HIV) tra...
HIV seroconversion outcomes in preexposure prophylaxis (PrEP) trials of oral tenofovir (TFV)-contain...
ABSTRACT To compare tissue-based pharmacokinetics and efficacy of oral tenofovir disoproxyl fumarate...
ObjectivesThis study evaluated the relationship between intracellular tenofovir diphosphate concentr...
ABSTRACT Tenofovir gel (1%) is being developed as a microbicide for the prevention of human immunode...
A vaginal gel containing 1 % tenofovir (TFV) was found to be safe and effective in reducing HIV infe...
<div><p>Topical preexposure prophylaxis (PrEP) against HIV has been marginally successful in recent ...
The development of animal models undergoing long-term antiretroviral treatment (ART) makes it possib...
ABSTRACT Tenofovir (TFV) is effective in preventing simian immunodeficiency virus (SIV) transmission...
Non-human primates (NHP) are widely used for the pre-clinical assessment of antiretrovirals (ARVs) f...
AbstractTransmission of drug-resistant HIV has been widely documented. We generated tenofovir (TFV)-...
Pre-exposure prophylaxis (PrEP) with emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) is a ...
Abstract Background: We reported previously that while prolonged tenofovir monotherapy of macaques i...
Daily pre-exposure prophylaxis (PrEP) with Truvada (a combination of emtricitabine (FTC) and tenofov...
Background: The goal of antiretroviral therapy (ART) is to suppress virus replication to limit immun...
Simple affordable interventions are needed to reduce vertical human immunodeficiency virus (HIV) tra...
HIV seroconversion outcomes in preexposure prophylaxis (PrEP) trials of oral tenofovir (TFV)-contain...
ABSTRACT To compare tissue-based pharmacokinetics and efficacy of oral tenofovir disoproxyl fumarate...
ObjectivesThis study evaluated the relationship between intracellular tenofovir diphosphate concentr...
ABSTRACT Tenofovir gel (1%) is being developed as a microbicide for the prevention of human immunode...
A vaginal gel containing 1 % tenofovir (TFV) was found to be safe and effective in reducing HIV infe...
<div><p>Topical preexposure prophylaxis (PrEP) against HIV has been marginally successful in recent ...
The development of animal models undergoing long-term antiretroviral treatment (ART) makes it possib...
ABSTRACT Tenofovir (TFV) is effective in preventing simian immunodeficiency virus (SIV) transmission...
Non-human primates (NHP) are widely used for the pre-clinical assessment of antiretrovirals (ARVs) f...
AbstractTransmission of drug-resistant HIV has been widely documented. We generated tenofovir (TFV)-...
Pre-exposure prophylaxis (PrEP) with emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) is a ...
Abstract Background: We reported previously that while prolonged tenofovir monotherapy of macaques i...
Daily pre-exposure prophylaxis (PrEP) with Truvada (a combination of emtricitabine (FTC) and tenofov...
Background: The goal of antiretroviral therapy (ART) is to suppress virus replication to limit immun...
Simple affordable interventions are needed to reduce vertical human immunodeficiency virus (HIV) tra...
HIV seroconversion outcomes in preexposure prophylaxis (PrEP) trials of oral tenofovir (TFV)-contain...